Prosecution Insights
Last updated: October 04, 2026
Application No. 18/528,393

PROTEIN KINETIC ENSEMBLE PLATFORM FOR DISCOVERY OF BINDING POCKETS AND NOVEL LIGANDS

Non-Final OA §101§102§112
Filed
Dec 04, 2023
Priority
Dec 02, 2022 — provisional 63/429,654
Examiner
KRIANGCHAIVECH, KETTIP
Art Unit
Tech Center
Assignee
Ensem Therapeutics Inc.
OA Round
1 (Non-Final)
19%
Grant Probability
At Risk
1-2
OA Rounds
2y 1m
Est. Remaining
48%
With Interview

Examiner Intelligence

Grants only 19% of cases
19%
Career Allowance Rate
11 granted / 57 resolved
-40.7% vs TC avg
Strong +29% interview lift
Without
With
+28.7%
Interview Lift
resolved cases with interview
Typical timeline
4y 11m
Avg Prosecution
23 currently pending
Career history
81
Total Applications
across all art units

Statute-Specific Performance

§101
31.6%
-8.4% vs TC avg
§103
28.7%
-11.3% vs TC avg
§102
12.5%
-27.5% vs TC avg
§112
18.8%
-21.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 57 resolved cases

Office Action

§101 §102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Status of claim Examined: 1 Independent: 1 Priority As detailed on the 02/08/2024 filing receipt, this claim benefit of U.S. Provisional Application No. 63/429,654 filed 12/02/2022. Drawings The drawings filed 12/04/2023 are accepted. Information Disclosure Statement No Information Disclosure Statements are provided. Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 1 is rejected under 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph, as based on a disclosure which is not enabling. The disclosure does not enable one of ordinary skill in the art to practice the invention. Claim 1 recites “A kinetic ensemble system....” The claim does not recite the physical structure associated with the recited system, which is/are critical or essential to the practice of the invention but not included in the claim(s). See In re Mayhew, 527 F.2d 1229, 188 USPQ 356 (CCPA 1976). Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claim particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claim particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 1 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites “A kinetic ensemble system....” The metes and bounds of the recited “system” are not clearly defined and renders the claim indefinite. It is unclear what components or structures are included in the system or what the system encompasses. Claim 1 recites “A kinetic ensemble system for identifying non-obvious target pockets and/or generating lead compound structures and/or structural components....” The metes and bounds of the recited “and/or” are not clearly defined and renders the claim indefinite. It is unclear whether the claim requires the steps of both identifying non-obvious target pockets and generating the lead compound… or is in the alternative where one of the steps is required. Similarly, it is unclear whether the claim requires both generating lead compound structures and structural components or is in the alternative where either the lead compound structures or structural components is generated. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Matter belonging to no statutory category -- claim 1 Claim 1 is rejected under 35 USC 101 because the claimed inventions are directed to non-statutory subject matter. Claim 1 is to "system," which is not, in all embodiments within a BRI, interpreted as belonging to any category listed in 101. In a BRI, the claim reads on data and/or software comprising no structure other than data and/or software. The claim is not recited as a process, and the claim is not limited to any particular structure as a 101 machine or manufacture. The claim reads on transitory propagating signals which are not proper patentable subject matter because it does not fit within any of the four statutory categories of invention (In re Nuijten, Federal. Circuit, 2006). Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Decherchi (Thermodynamics and Kinetics of Drug-Target Binding by Molecular Simulation. Chem. Rev. 9 December 2020; 120 (23): 12788–12833.; cited on the attached 892 form). Regarding independent claim 1, Decherchi teaches A system for identifying non-obvious target pockets and/or generating lead kinetic ensemble compound structures and/or structural components with “Structure−activity patterns determined by FEP for ligands of the induced myeloid leukemia cell differentiation protein Mcl-1. Differences of binding free energies (ΔΔG) between pairs of compounds compare favorably with experimental data” Figure 14 (caption, page 12811) and Figure 14. Decherchi teaches comprising computational components and experimental components or processes, wherein the computational components comprise: physics-based simulation and artificial intelligence; and the experimental components or processes comprise biophysical components and chemical biology components with “Thanks to growing computational power, physics-based simulation is becoming a more viable solution to computational drug discovery, whereas more approximate methods like docking have dominated until now. In this scenario, machine learning (ML) is playing an increasingly prominent role. Machine learning has been used for several years for protein− ligand binding studies in the form of QSAR289 or clustering/projection analysis of trajectories. Today, deep learning is widely available. The basic concepts of deep learning are not new and embody the paradigm of learning from data. Well designed computer libraries and GPUs have now made deep learning computationally feasible.” (page 12821, col. 1, para. 3). Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KETTIP KRIANGCHAIVECH whose telephone number is (571)272-1735. The examiner can normally be reached 8:30am-5:00pm EDT. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Larry D. Riggs can be reached at (571) 270-3062. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /K.K./Examiner, Art Unit 1686 /Karlheinz R. Skowronek/Supervisory Patent Examiner, Art Unit 1687
Read full office action

Prosecution Timeline

Dec 04, 2023
Application Filed
Sep 15, 2026
Non-Final Rejection mailed — §101, §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12597484
TRAIT PREDICTION COORDINATION FOR GENOMIC APPLICATION ENVIRONMENT
5y 8m to grant Granted Apr 07, 2026
Patent 12584844
FLOW CYTOMETRY IMMUNOPROFILING OF PERIPHERAL BLOOD
2y 4m to grant Granted Mar 24, 2026
Patent 12512185
DNA-BASED DATA STORAGE AND RETRIEVAL
5y 11m to grant Granted Dec 30, 2025
Patent 12415981
AUTOMATED COLLECTION OF A SPECIFIED NUMBER OF CELLS
6y 4m to grant Granted Sep 16, 2025
Patent 12364989
HIGH THROUGHPUT METHOD AND SYSTEM FOR ANALYZING THE EFFECTS OF AGENTS ON PLANARIA
6y 6m to grant Granted Jul 22, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
19%
Grant Probability
48%
With Interview (+28.7%)
4y 11m (~2y 1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 57 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month